TERN — Terns Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $332.31m
- $68.87m
- 34
- 30
- 28
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.3 | ||
| Price to Tang. Book | 1.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.97% | ||
| Return on Equity | -33.89% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1 | n/a | n/a | 1.67 | 2.9 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Directors
- David Fellows NEC (64)
- Erin Quirk PRE (50)
- Senthil Sundaram CEO (43)
- Mark Vignola CFO (43)
- Bryan Yoon COO (43)
- Diana Chung SVP
- Weidong Zhong CSO
- Ann Taylor DRC
- Carl Gordon IND (56)
- Jeffrey Kindler IND (64)
- Hongbo Lu IND (49)
- Jill Quigley IND (46)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 29th, 2020
- Public Since
- February 5th, 2021
- No. of Shareholders
- 7
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 64,651,693
- Address
- 1065 East Hillsdale Blvd., FOSTER CITY, 94404
- Web
- https://ternspharma.com/
- Phone
- +1 6505255535
- Auditors
- Ernst & Young LLP
Upcoming Events for TERN
Q2 2024 Terns Pharmaceuticals Inc Earnings Release
Similar to TERN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Terns Pharmaceuticals share price?
As of Today at 19:21 UTC, shares in Terns Pharmaceuticals are trading at $5.14. This share price information is delayed by 15 minutes.
How has the Terns Pharmaceuticals share price performed this year?
Shares in Terns Pharmaceuticals last closed at $5.14 and the price had moved by -56.37% over the past 365 days. In terms of relative price strength the Terns Pharmaceuticals share price has underperformed the S&P500 Index by -64.76% over the past year.
What are the analyst and broker recommendations for Terns Pharmaceuticals?
The overall consensus recommendation for Terns Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Terns Pharmaceuticals dividend yield?
Terns Pharmaceuticals does not currently pay a dividend.
Does Terns Pharmaceuticals pay a dividend?
Terns Pharmaceuticals does not currently pay a dividend.
When does Terns Pharmaceuticals next pay dividends?
Terns Pharmaceuticals does not currently pay a dividend.
How do I buy Terns Pharmaceuticals shares?
To buy shares in Terns Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Terns Pharmaceuticals?
As of the previous close price of $5.14, shares in Terns Pharmaceuticals had a market capitalisation of $332.31m.
Where are Terns Pharmaceuticals shares listed?
Here are the trading details for Terns Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TERN
What kind of share is Terns Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Terns Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Terns Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Terns Pharmaceuticals is $14.21. That is 176.46% above the last closing price of $5.14.
Analysts covering Terns Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.38 for the next financial year.
What is the trend in the Terns Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Terns Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -17.21%.
As of the last closing price of $5.14, shares in Terns Pharmaceuticals were trading -15.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Terns Pharmaceuticals PE Ratio?
The Terns Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Terns Pharmaceuticals?
Terns Pharmaceuticals' management team is headed by:
- David Fellows - NEC
- Erin Quirk - PRE
- Senthil Sundaram - CEO
- Mark Vignola - CFO
- Bryan Yoon - COO
- Diana Chung - SVP
- Weidong Zhong - CSO
- Ann Taylor - DRC
- Carl Gordon - IND
- Jeffrey Kindler - IND
- Hongbo Lu - IND
- Jill Quigley - IND